|View printer-friendly version|
|Illumina Awarded $26.7M in Patent Suit Against Ariosa Diagnostics, Inc.|
The jury found that both Ariosa’s previous and current version of the
Harmony non-invasive prenatal test (NIPT) infringe US Patent 8,318,430
and US Patent 7,955,794. The jury awarded
The jury rejected counterclaims by Ariosa that
The US Patent and Trademark Office previously upheld the validity of the patents rejecting multiple challenges filed by Ariosa.
“We are pleased with the outcome reached by the jury,” said
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.